Page last updated: 2024-08-21

azomycin and topotecan

azomycin has been researched along with topotecan in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cao, H; Chen, X; Chen, Y; Fan, J; Fu, S; Lin, S; Ren, P; Su, Z; Sun, X; Wu, J; Yang, B; Yang, L; Zhang, Y; Zhou, J; Zhou, Y; Zou, X	1
Baruchel, S; Kumar, S; Marrano, P; Thorner, P; Wu, B; Zhang, L	1

Other Studies

2 other study(ies) available for azomycin and topotecan

Article	Year
Synergistic effect of combination topotecan and chronomodulated radiation therapy on xenografted human nasopharyngeal carcinoma. International journal of radiation oncology, biology, physics, 2013, Oct-01, Volume: 87, Issue:2 Topics: Animals; Carcinoma; Cell Hypoxia; Chronotherapy; Combined Modality Therapy; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Radiation; Histones; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Nitroimidazoles; Phosphorylation; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous	2013
Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 06-01, Volume: 22, Issue:11 Topics: Activation, Metabolic; Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Inhibitory Concentration 50; Mice, Inbred NOD; Mice, SCID; Neuroblastoma; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Rhabdomyosarcoma; Topotecan; Xenograft Model Antitumor Assays	2016

Article

Year

Synergistic effect of combination topotecan and chronomodulated radiation therapy on xenografted human nasopharyngeal carcinoma.

International journal of radiation oncology, biology, physics, 2013, Oct-01, Volume: 87, Issue:2

Topics: Animals; Carcinoma; Cell Hypoxia; Chronotherapy; Combined Modality Therapy; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Radiation; Histones; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Nitroimidazoles; Phosphorylation; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous

2013

Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 06-01, Volume: 22, Issue:11

Topics: Activation, Metabolic; Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Inhibitory Concentration 50; Mice, Inbred NOD; Mice, SCID; Neuroblastoma; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Rhabdomyosarcoma; Topotecan; Xenograft Model Antitumor Assays

2016